drugset / Trial / NCT03740997

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

NCT03740997

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Study to determine the safety and appropriate dosage of OPTISON in pediatric participants since OPTISON has been tested in adult participants only during the clinical development

Timeline

Start
2020-12-01
Primary completion
2023-03-30
Completion
2023-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Optison Diagnostic / imaging agent 0.1 ml Intravenous
Subject Optison Diagnostic / imaging agent 0.2 ml Intravenous
Subject Optison Diagnostic / imaging agent 0.3 ml Intravenous
Subject Optison Diagnostic / imaging agent 0.4 ml Intravenous